THE DIALOG BETWEEN MANTLE CELL LYMPHOMA AND MONOCYTES/MACROPHAGES CAN BE DISRUPTED BY BTK INHIBITION AND MONITORED THROUGH CD163 MODULATION IN VIVO
EHA Learning Center, Antonin Papin, 214645
MOLECULAR PROFILE REFINES THE MRD-BASED PROGNOSTIC ASSESSMENT IN ADULTS WITH PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Jordi Ribera, 215245
THE PROGNOSIS FOR PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WHO WERE INELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE TKI ERA.
EHA Learning Center, Akio Shigematsu, 215262
CLINICAL AND BIOLOGICAL CHARACTERISTICS OF TWO DISTINCT T(16;21) FUSIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS BY THE I-BFM STUDY GROUP
EHA Learning Center, Sanne Noort, 215279
SINGLE CELL SIGNALING PHARMACODYNAMICS AND CLONAL EVOLUTION IN A PHASE 1/2 CLINICAL TRIAL OF SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB324) IN R/R ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
EHA Learning Center, Monica Hellesøy, 215296
IDENTIFYING A GENETICALLY DEFINED RISK GROUP OF PEDIATRIC AML PATIENTS THAT CANNOT BE RESCUED AT ALL AFTER THE FAILURE OF THE FIRST LINE TREATMENT
EHA Learning Center, Naghmeh Niktoreh Mofrad, 215312
IMPACT OF BCL2 AND ABCG2 OVEREXPRESSION IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Mario Tiribelli, 215328
GENETIC EVIDENCE IMPLYING THE COMMON PRECURSOR CELLS FOR PRIMARY AND EXTRA-CENTRAL NERVOUS SYSTEM RELAPSED TUMORS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
EHA Learning Center, Keiichiro Hattori, 215344
LIPOSOMAL DOXORUBICIN IN AGGRESSIVE B CELL LYMPHOMA SHOWS SIMILAR EFFICACY TO THE CONVENTIONAL FORMULATION: LONG TERM RESULTS FROM A RETROSPECTIVE COHORT STUDY
EHA Learning Center, Ana García-Noblejas, 215360
IDIOPATHIC NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY
EHA Learning Center, Piero Farruggia, 215376
PEMBROLIZUMAB (PEM) ACTIVITY IN CLL IS IMMUNE TO TUMOR MICROENVIRONMENTAL (TME) STIMULI
EHA Learning Center, Fortunato Morabito, 215392
EVALUATION OF THE INCIDENCE, RISK FACTORS, AND MANAGEMENT OF HYPERTENSION IN PATIENTS RECEIVING IBRUTINIB FOR HEMATOLOGIC MALIGNANCIES
EHA Learning Center, Farrukh Awan, 215409
ASXL1 MUTATIONS ARE FREQUENT IN CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS BUT NOT IN PATIENTS WITH OPTIMAL RESPONSE
EHA Learning Center, Marcin MACHNICKI, 215425
CROSS-INTOLERANCE WITH BOSUTINIB AFTER PRIOR TYROSINE KINASE INHIBITORS IN PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE LEUKEMIA: PHASE 1/2 STUDY UPDATE
EHA Learning Center, Jorge Cortes, 215441
SYNERGISTIC ANTITUMORAL EFFICACY OF A NOVEL REPLICATIVE ADENOVIRUS SG611-PDCD5 AND DAUNORUBICIN IN HUMAN LEUKEMIC CELLS
EHA Learning Center, Ya-Lan Zhou, 215458
ENHANCING BONE MARROW TREPHINE BIOPSY ANALYZES: DEFINING PEDIATRIC LYMPHOID SUBPOPULATION REFEERENCE RANGES BY AUTOMATED ENUMERATION
EHA Learning Center, Jacques Malherbe, 215474
EARLY INTERIM POSITRON EMISSION TOMOGRAPHY (PET) EVALUATION OF RESPONSE AFTER 2 ABVD CYCLES IN ADVANCED HODGIN LYMPHOMA (HL): 8-YEAR EXPERIENCE IN HELLENIC DEPARTMENTS – CONCLUSIONS AND LIMITATIONS
EHA Learning Center, Theodoros Vassilakopoulos, 215490
PEDIATRIC INTENSIVE CARE ADMISSIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Melpomeni Rompola, 215507
GENETIC STUDIES REVEAL NEW MUTATIONS IN THE CP GENE IN ACERULOPLASMINEMIA PATIENTS
EHA Learning Center, Giacomo Marchi, 215524
A FLOW-CYTOMETRY SCORING SYSTEM OF ABNORMAL GRANULOCYTES AND MONOCYTES MATURATION PROFILES FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Nicolas chapuis, 215540
FETAL HEMOGLOBIN INDUCTION DURING DECITABINE TREATMENT OF ELDERLY MDS/AML PATIENTS: A POTENTIAL DYNAMIC BIOMARKER FOR OUTCOME
EHA Learning Center, Julia Stomper, 215556
DEMETHYLATION SENSITISES T(4;14) MULTIPLE MYELOMA TO RAS-MAPK PATHWAY INHIBITION
EHA Learning Center, Jay Hocking, 215573
PAN-ANTI-FGF-BASED THERAPY AS A NOVEL THERAPEUTIC INTERVENTION IN WALDENSTROM’S MACROGLOBULINEMIA
EHA Learning Center, Antonio Sacco, 215589
EARLY LIGHT CHAIN KINETICS AND DEPTH/DURATION OF HEMATOLOGIC RESPONSES TO DARATUMUMAB IN PREVIOUSLY TREATED LIGHT CHAIN AMYLOIDOSIS
EHA Learning Center, Gregory Kaufman, 215605
IXAZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE FOR INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Heinz Ludwig, 215621
PHARMACOKINETIC EVALUATION OF TEST DOSE PREDICTIONS OF HIGH DOSE MELPHALAN EXPOSURE IN PATIENTS WITH MULTIPLE MYELOMA.
EHA Learning Center, Judith Trotman, 215637
ASSESSING SERUM ALBUMIN CONCENTRATION, LYMPHOCYTE COUNT AND PROGNOSTIC NUTRITIONAL INDEX MIGHT IMPROVE PROGNOSTICATION IN PATIENTS WITH MYELOFIBROSIS
EHA Learning Center, Marko Lucijanic, 215653
RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE EXPERIENCE IN ENGLAND, NORTHERN IRELAND AND WALES
EHA Learning Center, James Russell, 215669
WEE1 INHIBITION ENHANCES ANTI-APOPTOTIC DEPENDENCY OF DIFFUSE LARGE B-CELL LYMPHOMA CAUSED BY CELL CYCLE ARREST AND DNA DAMAGE INDUCTION
EHA Learning Center, Mathilde de Jong, 215686
CLINICAL CHARACTERISTICS AND TREATMENT COURSES FOR CYTOMEGALOVIRUS-ASSOCIATED THROMBOCYTOPENIA IN IMMUNOCOMPETENT CHILDREN AFTER NEONATAL PERIOD
EHA Learning Center, Ye Jee Shim, 215703
HOW TO IDENTIFY PATIENTS WITH MALIGNANT HEMOPATHIES WHO DON’T BENEFIT FROM STANDARD DOSE CHEMOTHERAPY
EHA Learning Center, Stéphanie Dubruille, 215720
EFFICACY AND SAFETY OF FACILITATED SUBCUTANEOUS IGG ADMINISTRATION IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DUE TO HEMATOLOGICAL MALIGNANCIES. A SINGLE-CENTER RETROSPECTIVE ANALYSIS.
EHA Learning Center, Maria Dimou, 215736
TARGETING EXPANDED GUT HOMING EFFECTOR T CELL LINEAGES IN ACUTE INTESTINAL GRAFT VERSUS HOST DISEASE: IMPLICATIONS FOR VEDOLIZUMAB
EHA Learning Center, Varun Mehra, 215753
ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMA IN SWITZERLAND. 30 YEARS OF EXPERIENCE 1985-2017.
EHA Learning Center, Stavroula Masouridi-Levrat, 215769
OUTCOMES OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSE OF HEMATOLOGICAL DISEASES OR GRAFT FAILURE: A SINGLE-CENTRE EXPERIENCE
EHA Learning Center, Monica Poiani, 215785
ASSOCIATION OF VITAMIN D AND RETINOID X RECEPTORS EXPRESSION AND VITAMIN D BINDING PROTEIN VARIANTS WITH BONE DENSITY IN THALASSEMIA CHILDREN
EHA Learning Center, shaimaa sahmoud, 215801
THE COAGULATION SYSTEM FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS
EHA Learning Center, Elizaveta Efremova, 215818
HIGH RISK AGGRESSIVE B-CELL LYMPHOMAS IDENTIFIED BY FISH: A MULTICENTRIC RETROSPECTIVE STUDY FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI
EHA Learning Center, Maria Chiara Tisi, 215898
TPL2 KINASE HAS A TUMOR SUPPRESSIVE ROLE IN MYC-INDUCED LYMPHOMAGENESIS
EHA Learning Center, ELIAS STAGAKIS, 215914
MOXETUMOMAB PASUDOTOX IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: RESULTS OF A PIVOTAL INTERNATIONAL STUDY
EHA Learning Center, Francis Giles, 214465
ALLOGENEIC STEM CELL TRANSPLANTATION FOR PERIPHERAL T-CELL LYMPHOMAS: A STUDY OF 284 PATIENTS FROM THE SOCIÉTÉ FRANCOPHONE DE GREFFE DE MOELLE ET DE THÉRAPIE CELLULAIRE.
EHA Learning Center, Stéphanie Nguyen Quoc, 214471
RAS PATHWAY HYPERACTIVATION IS ASSOCIATED WITH INFERIOR SURVIVAL IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Klaus Geissler, 214472
A PROSPECTIVE PHASE II STUDY OF DARATUMUMAB IN PREVIOUSLY-TREATED SYSTEMIC LIGHT- CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Arnaud Jaccard, 214545
RANDOMIZED COMPARISON OF 90 MG VERSUS 60 MG DAUNORUBICIN IN 7+3 STANDARD INDUCTION FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS FROM THE SAL-DAUNODOUBLE TRIAL
EHA Learning Center, Christoph Röllig, 214551
RITUXIMAB INDUCES A PRO-INFLAMMATORY MICROENVIRONMENT THAT INCREASES NOTCH1 SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS.
EHA Learning Center, Jennifer Edelmann, 214555
ANALYSIS OF ANTI-THROMBOPOIETIN RECEPTOR ANTIBODYIES IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Takashi Satoh, 214562
HEPCIDIN MIMETIC PTG-300 INDUCES DOSE-RELATED AND SUSTAINED REDUCTIONS IN SERUM IRON AND TRANSFERRIN SATURATION IN HEALTHY SUBJECTS
EHA Learning Center, Richard Shames, 214566
MESENCHYMAL STROMAL CELLS PROTECT ACUTE LYMPHOBLASTIC LEUKAEMIA CELLS FROM CYTARABINE INDUCED APOPTOSIS BY TRANSFER OF MITOCHONDRIA VIA TUNNELLING NANOTUBES IN A TREATMENT RESISTANT NICHE MODEL
EHA Learning Center, Richard Burt, 214611
UNEXPECTED PREVALENCES OF THE JAK2V617F AND CALR MUTATIONS IN THE GENERAL POPULATION
EHA Learning Center, Sabrina Cordua, 214616
VERY LOW DOSE PROPHYLAXIS IN CHILDREN WITH HAEMOPHILIA A: A RURAL INDIAN EXPERIENCE
EHA Learning Center, DIBYENDU DE, 215843
FINAL RESULTS OF A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA.
EHA Learning Center, Joseph Mikhael, 214463
DECREASED INCIDENCE OF INFECTION, USE OF ANTIBACTERIALS AND DAYS IN HOSPITAL AFTER ADMINISTRATION OF CLT-008 MYELOID PROGENITOR CELLS TO SUBJECTS RECEIVING AML INDUCTION THERAPY: PHASE 2 STUDY RESULTS
EHA Learning Center, Pinkal Desai, 214467
ATRA COULD CORRECT THE IMPAIRED PROPLATELET FORMATION CAUSED BY THE TUBULIN Β1 SINGLE NUCLEOTIDE POLYMORPHISM R307H IN CORTICOSTEROID-RESISTANT ITP PATIENTS
EHA Learning Center, Chen-cong Wang, 214474
A PHASE 1, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN PATIENTS WITH IRON OVERLOAD
EHA Learning Center, Vip Viprakasit, 214475
EFFICACY OF VENETOCLAX MONOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITION THERAPY.
EHA Learning Center, Toby Eyre, 214548
IBRUTINIB DOES NOT SUPPRESS CLONAL EVOLUTION IN HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Davide Rossi, 214554
PREDICTION OF LEUKEMIA FREE SURVIVAL FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML: A RISK SCORE DEVELOPED BY THE ALWP OF THE EBMT
EHA Learning Center, Roni Shouval, 214557
COMPARED ANALYSIS OF MUTATIONAL LANDSCAPE IN PEDIATRIC AND ADULT PATIENT WITH MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Wenbin An, 214558
CALRETICULIN DEL52 KNOCK-IN MICE DEVELOP A DOSE-DEPENDENT THROMBOCYTOSIS AND PROGRESSION TO MYELOFIBROSIS
EHA Learning Center, Caroline Marty, 214560
GENOMIC LANDSCAPE OF ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Li-Xin Wu, 214610
PHASE 1 FIRST-IN-HUMAN TRIAL OF AMV564, A BIVALENT BISPECIFIC (2×2) CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Peter Westervelt, 214466
KD025-208: A PHASE 2 OPEN-LABEL TRIAL OF KD025-208 FOR STEROID-DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
EHA Learning Center, Madan Jagasia, 214470
EFFECTS OF BONE MARROW MESENCHYMAL CELLS FROM IMMUNE THROMBOCYTOPENIA PATIENTS ON THE BIOLOGICAL BEHAVIORS OF MEGAKARYOCYTES
EHA Learning Center, Hua Zhong, 214473
CO-OCCURRENCE OF STAG2 AND RAS SIGNALING MUTATIONS DURING PROGRESSION FROM MDS TO SAML ANALYZED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING
EHA Learning Center, Marta Martín Izquierdo, 214496
A HISTIDINE PATCH IN THE N-DOMAIN OF MUTANT CALRETICULIN IS REQUIRED FOR MPN PATHOGENESIS
EHA Learning Center, Jeanne Rivera, 214497
ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
EHA Learning Center, Maria Victoria Mateos, 214544
PROSPECTIVE PHASE II STUDY OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED WALDENSTROM MACROGLOBULINEMIA (WM)
EHA Learning Center, Jorge Castillo, 214547
SYK TARGETING AS A POTENTIAL THERAPEUTIC STRATEGY FOR HIGH RISK TEL-AML1 PATIENTS
EHA Learning Center, Valentina Serafin, 214553
DEVELOPMENT OF A GALNAC SIRNA CONJUGATE TARGETING TMPRSS6 FOR THE TREATMENT OF IRON OVERLOAD DISORDERS, SUCH AS B-THALASSEMIA
EHA Learning Center, Ute Schaeper, 214565
MOR202 WITH LOW-DOSE DEXAMETHASONE (DEX) OR POMALIDOMIDE/DEX OR LENALIDOMIDE/DEX IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE I/IIA, MULTICENTER, DOSE-ESCALATION STUDY
EHA Learning Center, Marc Raab, 214462
ACALABRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
EHA Learning Center, Roger Owen, 214464
REGULATION OF HIF-1Α IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
EHA Learning Center, Marta Coscia, 214468
PANOBINOSTAT, DECITABINE, AND DONOR LYMPHOCYTE INFUSION POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE HOVON 116 STUDY IN NEWLY DIAGNOSED POOR-RISK AML PATIENTS
EHA Learning Center, Jan Cornelissen, 214550
GRAFT-VERSUS-LEUKEMIA EFFECTS IN SECONDARY ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Frederic Baron, 214556
DELETION OF STAT2 INCREASES THROMBOCYTOSIS AND SURVIVAL IN A JAK2 V617F MOUSE MODEL OF MPN VIA A NON CELL-AUTONOMOUS MECHANISM.
EHA Learning Center, Gaëlle Vertenoeil, 214559
LIVER IRON CONTENT DETERMINES HEPCIDIN LEVELS
EHA Learning Center, Sandro Altamura, 214564
MODELING HIGH RISK ACUTE LEUKEMIA WITH COMBINED T-CELL AND MYELOID PHENOTYPE CAUSED BY THE ETV6-NCOA2 FUSION GENE
EHA Learning Center, Hila Fishman, 214609
EZH2 AND RUNX1 MUTATIONS COLLABORATE TO INITIATE DISTINCT HEMATOLOGICAL MALIGNANCIES DEPENDING ON THE TARGET CELL
EHA Learning Center, Christopher Booth, 214614
NLRP3 INFLAMMSOME ACTIVATION IN PBMCS CONTROLS THE T CELL RESPONSE IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Mingqiang Hua, 214617
OPTIMISMM: PHASE 3 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW‐DOSE DEXAMETHASONE VS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN LENALIDOMIDE-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Paul Richardson, 214461
ADMINISTRATION OF BPX-501 CELLS FOLLOWING ALPHA/BETA T-CELL AND B-CELL-DEPLETED HLA HAPLOIDENTICAL HSCT (HAPLO-HSCT) IN CHILDREN WITH PRIMARY IMMUNODEFICIENCIES
EHA Learning Center, Daria Pagliara, 214469
MULTINATIONAL, RANDOMIZED PHASE 3 TRIAL OF IBRUTINIB-RITUXIMAB VS PLACEBO-RITUXIMAB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA.
EHA Learning Center, Meletios A Dimopoulos, 214546
PROSPECTIVE STUDY OF HLA-MATCHED DONOR AVAILABILITY AND SURVIVAL IN REMISSION AFTER AML IN OLDER ADULTS: 1ST PLANNED ANALYSIS FROM ECOG-ACRIN E2906 PHASE III RANDOMIZED TRIAL IN PATIENTS AGE ≥60 YEARS
EHA Learning Center, James Foran, 214549
PIGGYBAC TRANSPOSON SCREENING IDENTIFIES NOVEL CANCER GENES AND REGULATORY ELEMENTS IN T CELL LEUKEMIA
EHA Learning Center, Anja Pfaus, 214552
A STRATEGY WITH CHAPERONE-LIKE COMPOUNDS TO RESTORE EXPRESSION OF FACTOR IX VARIANTS AFFECTED BY FREQUENT MISSENSE MUTATIONS CAUSING HEMOPHILIA B
EHA Learning Center, Mirko Pinotti, 214561
INVESTIGATING THE ROLE OF NCOA4 IN ACUTE AND CHRONIC IRON RELEASE FROM STORES
EHA Learning Center, Antonella Nai, 214563
MULTIPLE MECHANISMS OF KRAS ACTIVATION IN TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Elena Vendramini, 214612
INTRINSIC DEFECTS CAUSED BY COMBINED CSNK1A1/RPS14 AND MIRNA145/146A DEFICIENCY DIRECTLY ALTER THE MICROENVIRONMENT IN A NOVEL MOUSE MODEL FOR DEL(5Q) MDS
EHA Learning Center, Flavia Ribezzo, 214613
A NOVEL INHIBITORY MUTATION FOR JAK2 V617F TARGETING THE AROMATIC INTERACTION AROUND F617 RESTORES NORMAL FUNCTION FOR MOST OF JAK2-UTILIZING CYTOKINE RECEPTORS EXCEPT IFNGR
EHA Learning Center, Emilie Leroy, 214615
Bispecific antibodies for ALL
EHA Learning Center, Christina Peters, 219185
CART cells
EHA Learning Center, Franco Locatelli, 219186
The imperative for change in adverse event reporting in hematologic malignancies
EHA Learning Center, Gita Thanarajasingam, 219187
Using patient-reported outcomes to improve toxicity assessment
EHA Learning Center, Fabio Efficace, 219188
Toxicity in hematologic malignancies: Considerations in bone marrow transplant, survivors and real world hematology patients
EHA Learning Center, John Gribben, 219189
Time trends in incidence rates of venous thrombosis
EHA Learning Center, Sigrid Braekkan, 219191
Future challenges in prevention and treatment of venous thrombosis
EHA Learning Center, John-Bjarne Hansen, 219192
Non-intensive treatment strategies in AML
EHA Learning Center, Gert Ossenkoppele, 219195
Intensive chemotherapy regimens in acute myeloide leukemia
EHA Learning Center, Je-Hwan Lee, 219196
Jean Bernard Lifetime Achievement Award: Lecture
EHA Learning Center, Charolotte Niemeyer, 219180
José Carreras Award lecture: Research challenges and therapeutic perspectives in APL
EHA Learning Center, Francesco Lo Coco, 219182

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings